New Non-Invasive Test for Lung Cancer Available Exclusively from LabCorp
September 23 2020 - 6:56AM
Business Wire
Blood-based test guides treatment decisions for
patients with non-small cell lung cancer
LabCorp (NYSE:LH), a leading global life sciences company that
is focused on advancing health and guiding patient care decisions,
has launched a new, non-invasive test for patients with non-small
cell lung cancer (NSCLC). Resolution ctDx Lung™ is a fast and
accurate liquid biopsy test that was developed and will be run by
Resolution Bioscience. The test is performed on a standard blood
sample and detects actionable mutations in genes associated with
NSCLC, providing valuable information to help select the most
effective targeted treatments for individual patients. The test is
covered by Medicare.
“Oncology is an area of intense focus for LabCorp, across our
entire organization,” said Dr. Brian Caveney, president of LabCorp
Diagnostics. “The Resolution ctDx Lung test is the latest example
of our commitment to provide patients and clinicians with
cutting-edge testing and personalized information to make the best
possible treatment decisions. This innovative test is an
outstanding addition to our industry leading offerings for oncology
patients.”
“This commercial partnership with LabCorp is an important step
in our quest to enable broad access to our lung cancer test and
improve clinical outcomes for more people battling NSCLC,” said
Mark Li, CEO of Resolution Bioscience. “The Resolution ctDx Lung
test consistently detects more driver and resistance mutations than
competing platforms. We are excited to be joining forces with
LabCorp to provide more physicians with the actionable information
needed to guide NSCLC therapy selection and patient care.”
To order the test, please contact LabCorp Oncology at
1-800-710-1800 or visit the LabCorp Oncology website for more
information.
The Resolution ctDx Lung test relies on the Resolution
Bioscience patented cell-free DNA (cfDNA) analysis platform, which
includes proprietary targeted capture next-generation sequencing
(NGS) biochemistry and tightly coupled, cloud-based bioinformatics.
Studies have demonstrated that the test offers greater sensitivity
than other currently available liquid biopsy tests for NSCLC. The
test has been cited in several important scientific publications
and presentations and is now being used to select the appropriate
plasma-directed therapy in an ongoing study of more than 1,000
patients with stage II, III, or IV NSCLC. Thus far, the study has
resulted in a positive clinical response of greater than 95%,
indicating that the test has significant utility in the choice of
appropriate therapy. For more information about the test, please
visit http://www.resolutionbio.com/assays/ctDx-Lung.html.
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global
life sciences company that is deeply integrated in guiding patient
care, providing comprehensive clinical laboratory and end-to-end
drug development services. With a mission to improve health and
improve lives, LabCorp delivers world-class diagnostics solutions,
brings innovative medicines to patients faster, and uses technology
to improve the delivery of care. LabCorp reported revenue of more
than $11.5 billion in 2019.
To learn more about LabCorp, visit www.LabCorp.com, and to learn
more about LabCorp’s drug development business, Covance, visit
www.Covance.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements,
including but not limited to statements with respect to clinical
laboratory testing, including the Resolution ctDX Lung™ test, the
impact of various factors on operating and financial results, and
the opportunities for future growth. Each of the forward-looking
statements is subject to change based on various important factors,
many of which are beyond the Company’s control, including without
limitation, competitive actions and other unforeseen changes and
general uncertainties in the marketplace, changes in government
regulations, including healthcare reform, customer purchasing
decisions, including changes in payer regulations or policies,
other adverse actions of governmental and third-party payers, the
Company’s satisfaction of regulatory and other requirements,
patient safety issues, changes in testing guidelines or
recommendations, adverse results in material litigation matters,
failure to maintain or develop customer relationships, our ability
to develop or acquire new products and adapt to technological
changes, failure in information technology, systems or data
security, and employee relations. These factors, in some cases,
have affected and in the future (together with other factors) could
affect the Company’s ability to implement the Company’s business
strategy and actual results could differ materially from those
suggested by these forward-looking statements. As a result, readers
are cautioned not to place undue reliance on any of our
forward-looking statements. The Company has no obligation to
provide any updates to these forward-looking statements even if its
expectations change. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement. Further
information on potential factors, risks and uncertainties that
could affect operating and financial results is included in the
Company’s most recent Annual Report on Form 10-K and subsequent
Forms 10-Q, including in each case under the heading RISK FACTORS,
and in the Company’s other filings with the SEC.
# # #
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200923005466/en/
LabCorp Contacts: Media: Donald Von Hagen — 336-436-8263
Media@LabCorp.com
Investors: Clarissa Willett —
336-436-5076 Investor@LabCorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024